TITLE

Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy

AUTHOR(S)
Rampton, D. S.
PUB. DATE
October 2005
SOURCE
Gut;Oct2005, Vol. 54 Issue 10, p1360
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The increased risk of active tuberculosis (TB) associated with infliximab makes necessary a screen for active and latent TB before this or other anti-tumour necrosis factor (TNF) treatment is begun in patients with Crohn's disease. This paper outlines how such screening should be undertaken, and Show to decide which patients need antituberculous treatment or chemoprophylaxis before infliximab. All patients need a careful history for TB and a chest x ray. The minority of patients with a history of TB or an abnormal chest x ray should be referred for assessment by a TB specialist. Of the remainder, those with Crohn's disease who are on immunosuppressive therapy do not require tuberculin testing. Comparison of their risk of TB while on anti-TNF therapy with the risks of chemoprophylaxis induced hepatitis indicates that black Africans aged over 15 years, South Asians born outside the UK, and other ethnic groups resident in the UK for less than live years should be considered for chemoprophylaxis with isoniazid for six months. For how to minimise the risk of TB in the small minority of patients with inflammatory bowel disease not on immunosuppressive treatment, readers are referred to the more detailed guidelines published in Thorax.
ACCESSION #
18457676

 

Related Articles

  • Management of Latent Tuberculosis during TNF Antagonist Administration.  // Clinical Infectious Diseases;9/15/2005, Vol. 41 Issue 6, preceding p1 

    The article cites a research study on management of Latent Tuberculosis during (Tumor Necrosis Factor) TNF Antagonist Administration. It informs that patients who receive TNF antagonists for treatment of rheumatologic or inflammatory bowel disease are at significantly increased risk of...

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment. Deleporte, Amélie; Viennot, Stéphanie; Dupont, Benoît; Gilletta, Cyrielle; Allaire, Manon; Prévost, Frédérique; Reimund, Jean-Marie // International Journal of Interferon, Cytokine & Mediator Researc;2013, Vol. 5, p11 

    Pathogenesis of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), continues to drive basic research to better decrypt their causal factor(s). Several key mediators involved in IBD pathogenesis have been identified and are considered as potential...

  • Management of inflammatory bowel disease. Nayar, M.; Rhodes, J. M. // Postgraduate Medical Journal;Apr2004, Vol. 80 Issue 942, p206 

    Ulcerative colitis and Crohn's disease result from an interaction between genetic and environmental factors. Only one gene, N002/CARO15, has been clearly identified; a minority of people with alteration of this gene develop Crohn's disease. The NOD2/CARD1 5 protein is thought to be involved in...

  • The classics in perspective. Panés, Julián; Ghosh, Subrata // Gut;Sep2007, Vol. 56 Issue 9, p1184 

    The authors reflect on the development of anti-cytokine therapies as biological agents in treating Crohn's disease and inflammatory diseases. Their therapeutic approach to these diseases has expanded. They noted that gastroenterologists face a remarkable wave of new biological therapies for...

  • TNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. LUPU, A.; TIERANU, C.; CONSTANTINESCU, C. L.; DICULESCU, M. // Current Health Sciences Journal;2014, Vol. 40 Issue 4, p285 

    Background: In patients with autoimmune diseases like inflammatory bowel diseases there has been reported a drug-induced lupus like syndrome secondary to TNFα inhibitors. Objective: clinical case presentation and literature review of patients who develop lupus-like syndrome in relation to...

  • Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Balzola, Federico; Bernstein, Charles; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 2, p80 

    The article discusses the survey of Australian gastroenterologists regarding the screening of patients with inflammatory bowel disease for infections prior to planned treatments. Survey participants deemed the importance of screening for latent tuberculosis infection and hepatitis B in the...

  • Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis: Evidence to Date. Thukral, Chandrashekhar; Cheifetz, Adam; Peppercorn, Mark A. // Drugs;2006, Vol. 66 Issue 16, p2059 

    Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-α, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a...

  • Management of Crohn's disease in poor responders to adalimumab. de Boer, Nanne K. H.; Löwenberg, Mark; Hoentjen, Frank // Clinical & Experimental Gastroenterology;2014, Vol. 7, p83 

    Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics